Join collection
Hello, welcome to our official website!
重磅!银保监会“三定”方案公布:9个内设机构被合并 内设机构“26+1”司局级干部107人
2019-01-12


在银保监会挂牌后7个月,该机构的“三定”方案终于正式公布。

11月13日,中国机构编制网公告了《中国银行保险监督管理委员会职能配置、内设机构和人员编制规定》(简称“三定”方案)。

根据“三定”方案,银保监会有26个内设部门,另设机关党委(党委宣传部)。记者梳理,有些部门系原有部门保留,有些部门系新增,有些部门系原有部门保留并合并,有些部门则系原有部门分拆后整合。原有的部分部门也在机构改革中被撤销。

银保监会机关事业编制925名。设主席1名,副主席4名,司局级领导职数107名(含机关党委专职副书记1名,机关纪委书记1名,首 席风险官、首 席检查官、首 席律师和首 席会计师各1名)。

详解内设机构

根据“三定”方案,银保监会有26个内设部门,另设机关党委(党委宣传部):

银保监会系统的人士也表示,对于人员的安置和分流上,此前有动议通过会管单位承接收等方式解决一部分,后来并没有大规模实施,主要是考虑回避制度。也有部分局级干部通过自主选择的方式,到了满足回避要求的金融机构。

今年3月,官方宣布银监会和保监会合并,组建新的银保监会。经历8个月的调整,中央编办于11月13日正式公布了银保监会的职能配置、内设机构和人员编制方案,即“三定”方案。

根据“三定”方案,银保监会为国务院正部级直属事业单位。其职责包括15项,主要对全国银行业和保险业实行统一监督管理。此外,还包括制定小额贷款公司、融资性担保公司、典当行、融资租赁公司、商业保理公司、地方资产管理公司等其他类型机构的经营规则和监管规则。制定网络借贷信息中介机构业务活动的监管制度。

在内设机构设置上,银保监会确定内设26个职能部门和1个机关党委。人员编制上,银保监会机关事业编制925名:其中,设主席1名,副主席4名,司局级领导职数107名,含机关党委专职副书记1名,机关纪委书记1名,**风险官、**检查官、**律师和**会计师各1名。

有银保监会系统人士向21世纪经济报道记者表示,“今年8月份"三定"方案就已经下发了,会机关的调整以及人员安排已经基本到位了。”

保留107名司局级干部

根据*新下发的“三定”方案,银保监会内设部门中,按机构属性进行功能监管的部门有政策银行部、大型银行部、股份制银行部、城市银行部、农村金融部、信托部、普惠金融部、创新部、非银部、财产保险部、人身保险部、保险中介监管部、保险资金运用监管部等。

其他的中后台部门,因为职责和功能类似,进行了合并。此前,原银监会共有24个内设实职部门,原保监会则有15个内设实职部门。在整合后的27个部门中,既有新设,也有合并,亦有撤销,而获保留的则占多数。

根据21世纪经济报道记者梳理,其中9个内设机构被合并,包括办公厅(党委办公室)、政策研究局、法规部、统计信息与风险监测部、财务会计部(偿付能力监管部)、消费者权益保护局、国际合作与外资机构监管部(港澳台办公室)、人事部(党委组织部)、机关党委(宣传部)。

3个新设机构,分别是公司治理监管部、非银行机构检查局、重大风险事件与案件处置局(银行业与保险业安全保卫局)。其中公司治理监管部主要负责“拟订银行业和保险业机构公司治理监管规则。协调开展股权管理和公司治理的功能监管。指导银行业和保险业机构开展加强股权管理、规范股东行为和健全法人治理结构的相关工作”。重大风险事件与案件处置局,将拟订银行业和保险业机构违法违规案件调查规则。组织协调银行业和保险业重大、跨区域风险事件和违法违规案件的调查处理等。

有银行业人士向21世纪经济报道记者表示:“两部委合并,职能部门必然面临大幅压缩,会机关机构的设置能看出监管的力量并没有削弱,压缩的多是中后台部门。”

在编制大为压缩的情况下,局级干部的安排是一个难点。“三定”方案确定的银保监会司局级领导职数107名,其中还包括了机关党委专职副书记1名,机关纪委书记1名,首 席风险官、首 席检查官、首 席律师和首 席会计师等4名。

银保监会系统的人士也表示,对于人员的安置和分流上,此前有动议通过会管单位承接收等方式解决一部分,后来并没有大规模实施,主要是考虑回避制度。也有部分局级干部通过自主选择的方式,到了满足回避要求的金融机构。

分支机构“三定”方案另出

在中央编办11月13日公布的“三定”方案中,暂时不包括地方的安排。该方案中也明确“银保监会派出机构、所属事业单位的设置、职责和编制事项另行规定”。

10月18日,21世纪经济报道也报道,银保监会已于当天宣布了36个银保监局筹备组的负责人。目前,银保监会分支机构的合并正在紧锣密鼓的筹备中,而且未来分支机构将进一步延伸至县级。

在银保监会近期的招考信息中也表示,银保监会全系统在全国设有省、市、县三级派出机构。2019年银保监会系统计划招录1214人。其中,省级派出机构327人,地市级派出机构543人,县级派出机构344人。

此前,银保监会的分支机构一般只设置到地市级,县级的监管还处于空白状况。但是央行在县级设有支行,有消息称,不排除将央行县级支行的部分人员和职能划归银保监系统,但具体还需要地方的“三定”方案明确。

近日,全国各省市的地方金融监管架构也在进行改革。据不完全统计,目前已有北京、上海、深圳、山东、河北、河南、吉林、山西、福建、重庆、广东、甘肃、江西、湖南、辽宁、四川等十几个省市的地方金融办升格为“金融监督管理局”,承担地方金融监管职责。

有地方银保监系统的人士向21世纪经济报道记者坦言:“今年P2P风险等集中暴露,也凸显了地方金融监管和中央金融监管体系衔接中的问题。下一步应该会对人民银行、银保监局派出机构以及地方金融监管局的职能和权责进行更加明确的划分。”(转自搜狐财经)

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online